The companion app patients use during their ketamine sessions.
Built by a biomedical engineer (M.Eng, Cornell) with 100+ personal Spravato sessions.
See how clinics are filling the 2-hour silence.
Katie Dickieson
Founder, We Be Now
“I spent 100+ sessions in your chairs asking: if my brain is at peak neuroplasticity, why is the app empty? Every feature is validated against my own clinical data.”
Peak neuroplasticity. A federally mandated 2-hour observation window where the brain is rewiring in real time — and what it encodes, persists.
You own it. Most clinics offer nothing. That gap is your competitive advantage — if you fill it before the clinic next door does.
A single sub-anesthetic dose of ketamine activates the mTOR pathway and triggers new dendritic spine synapse formation in the prefrontal cortex within 2 hours — a discrete neuroplastic window driving the antidepressant response.
Li N, Lee B, Liu RJ, et al. Science 2010;329(5994):959–964
We Be Now is built around this exact window — turning a neurochemical event into a directed plasticity event.
Spravato is available only through a restricted FDA REMS program — you control the 2-hour neuroplastic window completely. Every patient must be observed by a healthcare provider in a certified setting for at least 2 hours after each dose.
SPRAVATO (esketamine) US Prescribing Information, Janssen / FDA REMS, 2025 label
Your control of this window is the moat. No telehealth competitor can touch it. We Be Now is how you defend it.
In the pivotal TRANSFORM-2 trial, intranasal esketamine plus a newly initiated oral antidepressant produced ~50% remission and ~70% response rates in treatment-resistant depression.
Popova V, Daly EJ, Trivedi M, et al. Am J Psychiatry 2019;176(6):428–438
We Be Now is a durability and integration layer on top of these numbers — protecting the remission clinics already achieve.
Adjunctive psychotherapy and intentional ‘set and setting’ during and after dosing significantly enhance and prolong antidepressant response, leveraging the post-dose plasticity window.
Joneborg I, Lee Y, Di Vincenzo JD, et al. Frontiers in Psychiatry 2021;12:710338
The clinical rationale for We Be Now — a scalable integration protocol without requiring a therapist in the room.
600+ clinics · VC-backed clinical SaaS
Integrates with your workflow · patient-owned data feeds your outcomes
Limitless owns the clinical patient. We own the wellness-engaged one — and you own the outcomes data either way.
+ 19 more across meditations, hypnoses, breathing, soundscapes, EFT & chakra journeys
Each customizable to your dosing protocol (Spravato 56mg / 84mg, IV ketamine). Patients begin the session-specific track automatically upon check-in.
40% more of the treatment course completed when engagement milestones are surfaced (Linardon 2019). Engaged patients finish what they start.
Early clinics report 70–80% session-to-session follow-up rates via structured mood + insight tracking. We’ll commit to pilot data within 30 days.
Most clinics offer nothing during the federally-mandated 2-hour observation window. Patients notice. So do referring providers.
Patients self-serve through the app. No new FTE. No new workflow. Additive to existing observation, never a replacement.
The 2-hour observation requirement is preserved exactly as the prescribing information requires. We Be Now operates inside the existing clinical structure.
Encryption at rest + in transit, audit logging, role-based access. BAA available on any paid tier — SOC 2 documentation included at Clinic Plus and above.
| Metric | Conservative | Realistic |
|---|---|---|
| Patients enrolled / year | 50 | 150 |
| Avg revenue per completed course | $5,000 | $6,500 |
| Baseline completion rate | 45% | 50% |
| Lift from We Be Now retention | +4 pts | +8 pts |
| Recovered revenue / year | $10,000 | $78,000 |
| Annual license investment | $5,000 | $9,000 |
| Net annual benefit | $5,000 | $69,000 |
| ROI multiple | 2× | 8.7× |
Conservative model — Linardon meta-analysis effect size for app-based mental health interventions (g=0.28) translated to ketamine course completion. Real numbers discussed during pilot scoping.
“Most clinics earn back the license cost within the first 4 retained patients.”
“One retained Spravato patient pays for an entire year of Clinic tier. The math is one-sided.”
Annual billing: 2 months free on every tier · HIPAA-ready architecture, BAA available on any paid tier · Patients who self-discover us can subscribe direct on the App Store ($12.99/mo, $79/yr) — the clinic license unlocks the branded experience, clinician dashboard, and outcomes reporting they can’t get on the consumer app.
Sign a one-page Evaluation Agreement (NDA + eval license).
We Be Now installs on patient phones via TestFlight — no app store wait.
90-day pilot — patients use during sessions, you gather feedback.
Decide on a per-seat or annual license; we sign an MSA together.
You retain full control. We retain IP. Zero data sharing outside your clinic until you sign the MSA.
$0 upfront during the 90-day pilot. No license fee. No setup cost. No new FTE.
If you’re not seeing engagement lift by day 30, we stop. No questions, no clawback.
Your data stays with you. REMS-compliant by design, HIPAA-ready architecture — BAA available on any paid tier.
Additive to your existing observation workflow. Never a replacement. Patients self-serve.
Watch a 5-minute Loom walkthrough — or book a 15-minute Zoom.
hello@katiedickieson.comKatie Dickieson · Biomedical Engineer (M.Eng, Cornell) · Two-year Spravato + IV ketamine patient
We Be Now™ · 2024–2026 Katie Dickieson · All rights reserved.